CAT

866.32

-0.73%↓

324.23

+0.32%↑

GEV.US

949.44

-2.02%↓

RTX

174.37

-2.61%↓

224.43

-2.76%↓

CAT

866.32

-0.73%↓

324.23

+0.32%↑

GEV.US

949.44

-2.02%↓

RTX

174.37

-2.61%↓

224.43

-2.76%↓

CAT

866.32

-0.73%↓

324.23

+0.32%↑

GEV.US

949.44

-2.02%↓

RTX

174.37

-2.61%↓

224.43

-2.76%↓

CAT

866.32

-0.73%↓

324.23

+0.32%↑

GEV.US

949.44

-2.02%↓

RTX

174.37

-2.61%↓

224.43

-2.76%↓

CAT

866.32

-0.73%↓

324.23

+0.32%↑

GEV.US

949.44

-2.02%↓

RTX

174.37

-2.61%↓

224.43

-2.76%↓

Inicio・Lista de Acciones・Ocugen Inc

Ocugen Inc

Cerrado

1.36 -0.73

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.35

Máximo

1.38

Métricas clave
By Trading Economics
Ingresos	-1.5M -19M
Ventas	1.7M 1.5M
BPA	-0.06
Margen de beneficios	-1,250.946
Empleados	116
EBITDA	-987K -17M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+728.26% upside

Dividendos
By Dow Jones
Próximas Ganancias	31 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-173M 454M
Apertura anterior	2.09
Cierre anterior	1.36

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 jun 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 jun 2026, 23:38 UTC

Adquisiciones, fusiones, absorciones

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 jun 2026, 23:37 UTC

Charlas de Mercado

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 jun 2026, 23:01 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 23:01 UTC

Charlas de Mercado

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 jun 2026, 22:08 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Adquisiciones, fusiones, absorciones

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 jun 2026, 21:55 UTC

Adquisiciones, fusiones, absorciones

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 jun 2026, 21:53 UTC

Charlas de Mercado

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 jun 2026, 21:22 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

1 jun 2026, 20:46 UTC

Adquisiciones, fusiones, absorciones

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 jun 2026, 20:22 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Declares $11 Special Div

1 jun 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 jun 2026, 19:40 UTC

Charlas de Mercado

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 jun 2026, 19:28 UTC

Charlas de Mercado

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 jun 2026, 19:01 UTC

Charlas de Mercado

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 jun 2026, 18:58 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 jun 2026, 18:54 UTC

Adquisiciones, fusiones, absorciones

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 jun 2026, 18:33 UTC

Charlas de Mercado

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 jun 2026, 18:32 UTC

Charlas de Mercado

Precious Metals Fall to Start June -- Market Talk

1 jun 2026, 18:00 UTC

Adquisiciones, fusiones, absorciones

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 jun 2026, 17:18 UTC

Charlas de Mercado

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 jun 2026, 17:18 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 17:10 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

728.26% repunte

Estimación a 12 Meses

Media 11.43 USD 728.26%

Máximo 22 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.